Sign in
QURE Stock Price, Chart, Stats & News
uniQure N.V.
Save
3.08B
Market cap
–
Current P/E
27.93x
Forward P/E
QURE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 71.08% |
Operating margin | -1157.86% |
Pretax margin | -1201.02% |
Net margin | -1236.00% |
Effective tax rate | -2.91% |
ROA | -24.12% |
ROE | -174.03% |
D/E | 2.70x |
Interest coverage ratio | -3.01x |
QURE valuation
P/E | – |
P/S | 56.52x |
P/B | 4.27x |
P/CF | -4.77x |
P/FCF | -5.11x |
P/OCF | -4.77x |
PEG | -0.21x |
EV multiple | -3.19x |
About
uniQure N. V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Similar securities
Based on sector and market capitalization
Report issue